NCT05597085 - A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

July 10, 2023

Study Completion Date

July 10, 2023

Conditions

Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Interventions

DRUG

Inotuzumab Ozogamicin

Inotuzumab Ozogamicin is an Antibody drug conjugate directed against CD 22 positive B Cell ALL

Trial Locations (5)

Rajiv Gandhi Cancer Institute and Research Centre, New Delhi

Fortis Memorial Research Institute, Gurugram

Indo-American Cancer & Research Centre, Hyderabad

Malabar Cancer Center, Thalassery

Tata Medical Center, Kolkata